Amendments to the Claims:

The following listing of claims will replace any/all prior versions, and listings, of claims in the application, wherein additions are shown in underlined text and deletions are shown in strike-out text:

Claim **1** (Currently Amended) A method of treating ~~an individual suffering from~~ chronic pain associated with peripheral neuropathy, the method comprising ~~the step of~~ administering to ~~the~~ an individual ~~a therapeutically effective amount of~~ in need of treatment optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount to treat such chronic pain.

Claim **2** (Previously Presented) The method of claim **1** wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.1 to about 10 mg/day.

Claim **3** (Previously Presented) The method of claim **2** wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 8 mg/day.

Claim **4** (Previously Presented) The method of claim **3** wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 5 mg/day.

Claim **5** (Previously Presented) The method of claim **4** wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 2.5 mg/day.

Claim **6** (Previously Presented) The method of claim **5** wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.9 mg/day.

Claim **7** (Previously Presented) The method of claim **6** wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.8 mg/day.

Claim **8** (Previously Presented) The method of claim **7** wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.75 mg/day.

Claim **9** (Previously Presented) The method of claim **1** wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered as a composition and said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally.

Claim **10** (Original) The method of claim **9** wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the group consisting of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, wetting agent, and mixtures thereof.

Claim **11** (Original) The method of claim **10** wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim **12** (Previously Presented) The method of claim **9** wherein said composition is parenterally administered subcutaneously, intravenously, or intramuscularly.

Claim **13** (Canceled).

Claim **14** (Previously Presented) The method of claim **1** wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

Claim **15** (Currently Amended) The method of claim **1** wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt.% of (S,S) reboxetine, and less than about 10 wt.% of (R,R) reboxetine, based on the total weight of (S,S) and (R,R) reboxetine present.

Claim **16** (Currently Amended) The method of claim **15** wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt.% of (S,S) reboxetine and less than about 3 wt.% of (R,R) reboxetine, based on the total weight of (S,S) and (R,R) reboxetine present.

Claim **17** (Currently Amended) The method of claim **16** wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt.% of (S,S) reboxetine and less than about 1 wt.% of (R,R) reboxetine, based on the total weight of (S,S) and (R,R) reboxetine present.

Claims **18-67** (Cancelled).